NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

August 3, 2024

Primary Completion Date

August 3, 2025

Study Completion Date

February 3, 2026

Conditions
Atrial FibrillationCardiovascular DiseasesArrhythmiaValvular Disease
Interventions
OTHER

TEMPUS AI-enabled ECG-based Screening Tool

The AI-enabled ECG-based screening tool, Tempus Next software, analyzes 12-lead ECG recordings to identify patients at increased risk for undiagnosed cardiovascular diseases, specifically atrial fibrillation (AF) and structural heart disease (SHD). Clinicians in the intervention group will receive a risk assessment for AF and SHD each time they order an ECG for their patients.

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER